About Rosetta Genomics
Rosetta Genomics is a company based in Philadelphia (United States) founded in 2000 was acquired by Genoptix in December 2017. Rosetta Genomics has raised $4 million across 9 funding rounds from investors including Teva Pharmaceuticals, Prometheus Laboratories and European Union. Rosetta Genomics operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Philadelphia, United States
- SectorsHealthcare
- Email••••••••
- Website rosettagx.com
- Social LinkedIn X Facebook
- Acquired by Genoptix (Dec 2017)
- Total Equity Funding$4M (USD)
in 9 rounds
- InvestorsTeva Pharmaceuticals
& 14 more
- Acquired byGenoptix
(Dec 2017)
Funding Insights of Rosetta Genomics
Rosetta Genomics has successfully raised a total of $4M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 9
- First Round $4M
(Mar 2005)
- Investors Count 14
All 9 funding rounds of Rosetta Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | – | Grant | – | – | |
| Aug 2013 | – | Grant | – | – | – |
| Feb 2012 | $1.75M | Post-IPO | – | – | – |
| Oct 2011 | $1.52M | Post-IPO | – | – | – |
| Mar 2011 | $2.73M | Post-IPO | – | – | – |
| Jan 2011 | $460,000 | Grant | – | – | – |
| Dec 2010 | $2.5M | Post-IPO | – | – | – |
| Apr 2009 | $8M | Post-IPO | – | – | |
| Mar 2005 | $4M | Series A | – | Teva Pharmaceuticals, GlenRock Israel |
15 investors in total: 6 institutional and 9 angel.
Investors in Rosetta Genomics
Rosetta Genomics has secured backing from 15 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Teva Pharmaceuticals, Prometheus Laboratories and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are targeted in Israel and the US. | – | grg.co.il | Herzliya, Israel | |
Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed. | 1995 | prometheuslabs.com | San Diego, United States | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel | |
Stem cell therapies for diabetes and ALS are developed. | 2009 | kadimastem.com | Ness Ziona, Israel | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
YS Yair Shamir | Israeli entrepreneur, angel investor, and chairman of Catalyst Investments, active in India. | – | unknown_f57a35b612df4cc9b | - |
MA Mori Arkin | - | – | unknown_52897ff8d4ff43889 | - |
UG Uzia Galil | - | – | unknown_aaed00b8905e40368 | - |
YC Yoav Chelouche | Israeli VC and angel investor, active in India, Managing Partner at Aviv Ventures | – | unknown_e3310caeb4cb476ab | - |
AL Ami Lidor | - | – | unknown_6786479237d04dd3a | - |
Investor details for Rosetta Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Rosetta Genomics
4 dated milestones of Rosetta Genomics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Rosetta Genomics is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Grant,.
- Exit Acquired by Genoptix.
Competitors of Rosetta Genomics
Rosetta Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of Rosetta Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rosetta Genomics
Complete news archive for Rosetta Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Rosetta Genomics
10 companies that operate in the same segment as Rosetta Genomics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Rosetta Genomics
Rosetta Genomics was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Rosetta Genomics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Rosetta Genomics is a funded company, having raised a total of $4M across 9 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Mar 2005.
RosettaGX develops genetic tests for cancer. It offers a variety of proprietary assays that use FISH, miRNA analysis and next-generation sequencing. Its Cancer Origin Test enables physicians to discover the exact source of cancers of unknown origin. OncoGxOne and OnocGxLung use next generation sequencing for genomic profiling solid tumors and lung cancer. Reveal uses advanced miRNA expression analysis to determine necessity of surgery for thyroid cancer. In addition, the company also provides FISH and PCR assays for lung, prostate, bladder, breast and kidney cancers.
Rosetta Genomics's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Rosetta Genomics has 15 investors. Key investors include Teva Pharmaceuticals, Prometheus Laboratories, European Union, Kadimastem, and Genoptix.
Yes. Rosetta Genomics was acquired by Genoptix in December 2017.